Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment-Reference-Cited by-同舟云学术

Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment

Published:2014-02 Issue:2 Volume:15 Page:201-208
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Luo Jian-Quan¹,Wang Lu-Yan²,He Fa-Zhong¹,Sun Ning-Ling²,Tang Gen-Fu³,Wen Jia-Gen¹,Luo Zhi-Ying¹,Liu Zhao-Qian¹,Zhou Hong-Hao¹,Chen Xiao-Ping¹,Zhang Wei⁴

Affiliation:

1. Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, Hunan 410078, PR China

2. Department of Cardiology, People’s Hospital, Peking University, Beijing 100044, PR China

3. School of Health Administration, Anhui Medical University, Hefei 230032, PR China

4. Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, Hunan 410078, PR China.

Abstract

Aim: The mineralocorticoid receptor (MR; also known as NR3C2) plays important roles in the modulation of blood pressure. The effect of NR3C2 polymorphisms on antihypertensive response to enalapril was investigated. Patients & methods: Two hundred and seventy nine essential hypertension patients treated with enalapril were genotyped for two NR3C2 tagSNPs, rs5522 and rs2070950, by Sequenom MassArray™ technology. Results: The reductions in diastolic blood pressure (DBP) were significantly greater in AA homozygotes compared with AG+GG genotype carriers for the rs5522 polymorphism (p = 0.009), and the reductions in DBP were greater in GG homozygotes compared with GC+CC genotype carriers for the rs2070950 polymorphism, with marginal significance (p = 0.065). Stepwise multiple regression analysis indicated that significant predictors of DBP reduction were baseline DBP (p < 0.001), waist:hip ratio (p = 0.001) and rs5522 genotype (p = 0.003). Conclusion:NR3C2 rs5522 affects blood pressure response to enalapril treatment and may serve as a useful pharmacogenomic marker of antihypertensive response to enalapril in essential hypertension patients. Original submitted 8 August 2013; Revision submitted 29 August 2013; Published online 23 September 2013

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs.13.173

Reference31 articles.

1. The Renin-Angiotensin-Aldosterone System: Approaches to Guide Angiotensin-Converting Enzyme Inhibition in Patients with Coronary Artery Disease

2. Influence of the Angiotensin II Type 1 Receptor Gene Polymorphism on the Effects of Perindopril and Nitrendipine on Arterial Stiffness in Hypertensive Individuals

3. Relationship Between the Response to the Angiotensin Converting Enzyme Inhibitor Imidapril and the Angiotensin Converting Enzyme Genotype

4. A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals

5. Book Review Respiratory Infections: A Scientific Basis for Management Edited by Michael S. Niederman, George A. Sarosi, and Jeffrey Glassroth. 657 pp., illustrated. Philadelphia, W.B. Saunders, 1994. $125. 0-7216-4347-7

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence on the Impact of Pharmacogenetics to Treat and Manage Cardiovascular Diseases;Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy;2023

2. Evidence on the Impact of Pharmacogenetics to Treat and Manage Cardiovascular Diseases;Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy;2023

3. The clinical impact of anti-hypertensive treatment drug-gene pairs in the asian population: a systematic review of publications in the past decade;Journal of Human Hypertension;2022-10-27

4. Peripheral Blood Transcripts Predict Preoperative Obstructive Total Anomalous Pulmonary Venous Connection;Frontiers in Cardiovascular Medicine;2022-05-31

5. NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo‐DHF trial;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2021-10-12